Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
NCT06811324
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity Prevention
- Sarcopenia in Elderly
- Cardiovascular Function
- GLP - 1
- Weight Loss
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Last updated on ClinicalTrials.gov
- April 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- University of Texas Health Science Center at San Antonio · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.